Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
1.900
+0.340 (21.79%)
At close: Aug 22, 2025, 4:00 PM
1.960
+0.060 (3.16%)
After-hours: Aug 22, 2025, 7:59 PM EDT
Equillium Employees
Equillium had 35 employees as of December 31, 2024. The number of employees decreased by 9 or -20.45% compared to the previous year.
Employees
35
Change (1Y)
-9
Growth (1Y)
-20.45%
Revenue / Employee
$472,943
Profits / Employee
-$576,971
Market Cap
113.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35 | -9 | -20.45% |
| Dec 31, 2023 | 44 | 8 | 22.22% |
| Dec 31, 2022 | 36 | -9 | -20.00% |
| Dec 31, 2021 | 45 | 14 | 45.16% |
| Dec 31, 2020 | 31 | 15 | 93.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EQ News
- 13 days ago - Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic - Business Wire
- 20 days ago - Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy - Business Wire
- 3 months ago - Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - Business Wire
- 4 months ago - Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - Business Wire
- 4 months ago - Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
- 5 months ago - Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients - Benzinga
- 5 months ago - Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Business Wire
- 5 months ago - Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Business Wire